查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1371914

到 2030 年生物標記測試服務市場預測：按測試類型、技術、應用、最終用戶和地區進行的全球分析

Biomarker Testing Services Market Forecasts to 2030 - Global Analysis By Testing Type, By Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球生物標記檢測服務市場規模為 9.082 億美元，預計預測期內年複合成長率為 8.9%，到 2030 年將達到 1.6619 億美元。

一種測試程序，用於搜尋組織、血液或其他體液樣本中的特定基因、蛋白質或其他可能是某種疾病或疾病（例如癌症）跡象的物質。此外，生物標記測試有時用於尋找可能增加癌症或其他疾病風險的染色體或遺傳異常。生物標記測試以及切片檢查等其他程序可以幫助診斷某些癌症。

根據 ClinicalTrials.gov 統計，2018 年註冊試驗超過 262,298 項，截至 2022 年 9 月，註冊試驗超過 399,518 項。隨著臨床研究經費的增加，臨床試驗預計在未來幾年將會改善。預計這將增加對藥物研發研究的需求，從而增加疫情後時代對生物標記測試的需求。

慢性病發生率增加和技術進步

隨著糖尿病、心血管疾病和癌症等慢性病的罹患率增加，對生物標記檢測服務的需求也增加。生物標記對於這些疾病的早期檢測、診斷和監測極為重要。此外，技術的發展徹底改變了生物標記測試領域。質譜、次世代定序、高通量篩選方法和免疫分析都在提高生物標記分析的精確度和有效性。由於這些發現和技術進步，預計市場在預測期內將實現盈利成長。

與調查相關的高成本

全球生物標記研究服務市場的快速擴張可能會受到生物技術和製藥公司無法進行生物標記研究以及開發新藥所需的研究成本高昂的限制。此外，成本效益低、樣本採集和儲存方面的技術挑戰以及法規和報銷框架不足是未來年度全球生物標記研究服務市場開拓的潛在障礙，但這是可能的。

加大研發投入

推動市場擴張的關鍵因素包括藥物研發投資的增加、癌症治療中對精準醫療的需求不斷增加以及感染疾病和慢性病負擔的增加刺激了對生物標記檢測的需求。此外，過去年度來，臨床試驗的數量穩定增加。根據 ClinicalTrials.gov 統計，2018 年註冊試驗超過 262,298 項，截至 2022 年 9 月，註冊試驗超過 399,518 項。隨著臨床研究資金的增加，臨床試驗預計在未來幾年會變得更好。在大流行後時代，對藥物研發研究和最終生物標記測試的需求預計將會增加。

缺乏熟練的專業人員

由於醫療保健部門缺乏合格且經驗豐富的專業人員，全球生物分析測試服務市場的擴張受到阻礙。測試程序使用最尖端科技和採樣，因此合格的醫務人員對於藥物開發和測試都至關重要。為了進行測試，實驗室和研究設施需要經過訓練的人員。否則，缺乏合格人員可能會帶來健康風險並降低技術採用率。這些因素共同限制了市場的擴張。

COVID-19 的影響：

COVID-19 大流行對生物標記測試服務市場產生了重大影響。在最初因醫療設施關閉和就診人數減少而受到干擾後，隨著診斷測試、血清學測試和疫苗功效研究變得更加重要，對生物標記測試的需求激增。生物標記測試在識別和監測 COVID-19 病例、推進治療方法和疫苗研究以及評估其有效性方面發揮了至關重要的作用。這次疫情加速了這一領域的創新，促進了新型生物標記和診斷技術的發展。大流行之後，市場繼續成長，因為醫療保健系統優先考慮早期疾病檢測和個人化醫療，凸顯了生物標記測試服務的重要性。

生物製藥和製藥公司部門預計將在預測期內成為最大的部門

預計製藥和生物技術公司領域將在預測期內佔據最大的市場佔有率。推動該領域成長的主要因素之一是製藥和生物技術產業為臨床研究提供的資金不斷增加。這就是Astra Zeneca和羅氏於 2022 年 9 月聯手重塑中東和北非癌症診斷和治療的原因。此外，製藥公司對開發標靶癌症療法的興趣日益濃厚，這也促進了該領域的成長。

血清學免疫抗原性/中和抗體片段預計在預測期內出現最高的年複合成長率

在預測期內，血清免疫抗原性和中和抗體領域預計將出現良好的成長。需要這些測試來評估臨床前模型中的免疫反應，使用臨床樣本來尋找響應治療而產生的抗體。它提高了疫苗和生技藥品製造流程的可靠性，同時能夠評估功效和安全性。在單株抗體 (mAb) 開發的臨床階段，擴大使用基於血清學、免疫抗原性和中和抗體的測試，以確保反應不會威脅患者安全。這推動了該領域生物分析測試的需求。

佔比最大的地區：

預計北美將在預測期內主導市場。該地區存在提供生物標記測試服務的主要市場參與者，這是支持該地區市場的因素之一。此外，複雜的醫療基礎設施的存在、疾病負擔的增加導致實驗室診斷測試數量的增加以及公共機構研發投資的增加正在推動該地區的市場擴張。

複合年複合成長率最高的地區：

由於製藥和生物技術研發業務的資金增加，預計歐洲地區在預測期內將快速成長。心血管疾病的增加也是推動歐洲市場的因素。此外，糖尿病是該地區的一個主要問題。過去年度來，該地區一些國家的糖尿病發生率顯著增加，有時增加超過 50%。因此，所有這些因素預計將在預測期內推動市場成長。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場公司的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 技術分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球生物標記測試服務市場：依測試類型

  • 生物標記測試
  • 基於細胞的檢測
  • 方法開發最佳化和檢驗
  • 藥物動力學研究
  • 血清學免疫抗原性和中和抗體
  • 毒理學服務
  • 病毒測試
  • 其他類型的測試

第6章 全球生物標記測試服務市場：依技術分類

  • 質譜
  • 色譜法

第7章 全球生物標記測試服務市場：依應用分類

  • 神經病學
  • 心臟病學
  • 消化內科
  • 血液學
  • 免疫學
  • 感染疾病
  • 代謝紊亂
  • 腫瘤學
  • 整形外科
  • 其他用途

第8章 全球生物標記測試服務市場：依最終用戶分類

  • 生物製藥和製藥公司
  • 合約開發/製造組織
  • 受託研究機構
  • 醫療機構
  • 其他最終用戶

第9章 全球生物標記測試服務市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第10章 進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章公司簡介

  • Euro fins Scientific
  • Abbott Laboratories
  • Bio Agilytix Labs
  • Bio-Rad Laboratories, Inc.
  • Charles River Laboratories
  • Epigenetics AG
  • F. Hoffmann-La Roche Ltd.
  • ICON Plc
  • Intertek Group Plc
  • IQVIA
  • Johnson & Johnson Services, Inc.
  • Labcorp Drug Development
  • Qiagen
  • SGS SA
  • Siemens Healthineers AG
  • Syneos Health
  • Thermo Fisher Scientific, Inc.
Product Code: SMRC23971

According to Stratistics MRC, the Global Biomarker Testing Services Market is accounted for $900.82 million in 2023 and is expected to reach $1636.19 million by 2030 growing at a CAGR of 8.9% during the forecast period. A laboratory procedure that looks for specific genes, proteins, or other substances that may be a symptom of a disease or illness, such as cancer, in a sample of tissue, blood, or other bodily fluid. Additionally, biomarker testing can be used to check for chromosomal or gene anomalies that may increase a person's risk of developing cancer or other diseases. The use of biomarker testing in conjunction with other procedures, like biopsies, can help diagnose some cancers.

According to ClinicalTrials.gov, more than 262,298 studies were registered in 2018, while more than 399,518 trials were registered as of September 2022. Clinical trials are projected to improve in the future years as clinical research funding increases. This is predicted to increase demand for drug discovery research and, as a result, demand for biomarker testing in the post-pandemic era.

Market Dynamics:

Driver:

Increasing incidence of chronic illnesses and technological advancements

The demand for biomarker testing services is rising as the prevalence of chronic diseases like diabetes, cardiovascular disease, and cancer rises. In the early detection, diagnosis, and monitoring of these diseases, biomarkers are extremely important. In addition, technological developments have transformed the field of biomarker testing. Mass spectrometry, next-generation sequencing, high-throughput screening methods, and immunoassays have all improved the precision and effectiveness of biomarker analysis. As a result of these discoveries and technological advancements, the market is predicted to grow profitably during the forecast period.

Restraint:

High cost associated with research

The rapidly expanding global market for biomarker research services may be constrained by biotechnology and pharmaceutical companies' inability to conduct biomarker research and by the high cost of conducting the research required for the development of new drugs. Moreover, low cost-to-benefit ratios, technical challenges with sample collection and storage, and inadequate regulatory and reimbursement frameworks are additional potential roadblocks that may hinder the development of the global market for biomarker research services in the years to come.

Opportunity:

Growing investment in R&D

Some of the key factors propelling market expansion include increasing investments in pharmaceutical R&D, the growing demand for precision medicine used in cancer therapy, and an increase in the burden of infectious and chronic diseases fueling demand for biomarker testing. Furthermore, over the previous five years, the number of clinical trials has been steadily rising. ClinicalTrials.gov reports that more than 262,298 studies were registered in 2018 and that, as of September 2022, there were more than 399,518 trials registered. Clinical trials are expected to get better in the coming years as funding for clinical research rises. In the post-pandemic era, it is anticipated that this will lead to a rise in demand for drug discovery research and, consequently, for biomarker testing.

Threat:

Lack of skilled professionals

The expansion of the global market for bioanalytical testing services is being hampered by a lack of qualified or experienced professionals in the healthcare sector. Due to the use of cutting-edge technologies and sampling in testing procedures, qualified medical personnel are essential for both drug development and testing. In order to conduct the tests, laboratories and research facilities need trained personnel; otherwise, a lack of qualified staff may result in health risks, which would lower the technology's adoption rate. These factors limit market expansion as a whole.

COVID-19 Impact:

The COVID-19 pandemic has significantly impacted the biomarker testing services market. While there was an initial disruption due to lockdowns and reduced healthcare visits, the demand for biomarker testing surged as diagnostic tests, serology tests, and vaccine efficacy studies became critical. Biomarker testing played a pivotal role in identifying and monitoring COVID-19 cases, driving research for therapies and vaccines, and assessing their effectiveness. The pandemic accelerated innovation in the field, leading to the development of novel biomarkers and diagnostic technologies. Post-pandemic, the market continues to grow as healthcare systems prioritize early disease detection and personalized medicine, underscoring the importance of biomarker testing services.

The biopharmaceutical and pharmaceutical companies segment is expected to be the largest during the forecast period

During the forecast period, the pharmaceutical and biotechnology companies segment is anticipated to have the largest market share. One of the main factors driving the segment's growth is an increase in the funding provided by the pharmaceutical and biotechnology industries for clinical research. Due to this, AstraZeneca and Roche partnered in September 2022 to reimagine cancer diagnosis and treatment in the Middle East and North Africa. Additionally, pharmaceutical companies are becoming more interested in creating targeted cancer therapies, which is contributing to segment growth.

The serology immunogenicity and neutralizing antibodies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the serology immunogenicity and neutralizing antibodies segment is anticipated to have lucrative growth. To find antibodies produced against a treatment, these tests are required for assessing the immune response in preclinical models using clinical samples. It increases the dependability of the production process for vaccines and biologics while enabling the organization to assess efficacy and safety. The growing use of serology, immunogenicity, and neutralizing antibody-based testing during the clinical phase for the development of monoclonal antibodies (mAbs) to ensure that the response does not jeopardize patient safety is driving up demand for bioanalytical testing in this segment.

Region with largest share:

During the period of the forecast, North America is anticipated to dominate the market. Major market players who provide services for biomarker testing are present in the region, which is one of the factors supporting the market in the area. Additionally, the presence of sophisticated healthcare infrastructure, the rise in disease burden that leads to an increase in laboratory diagnostic testing, and growing R&D investment by public organizations in the region are driving market expansion in this region.

Region with highest CAGR:

Owing to increasing funding for pharmaceutical and biotechnology R&D operations, the Europe region is expected to grow quickly over the forecast period. The rise in cardiovascular disease is another factor driving the market in Europe. Additionally, diabetes is a major problem in this region. It has increased significantly in several countries in the region over the past ten years, sometimes by more than 50%. All of these factors are therefore anticipated to boost market growth during the forecast period.

Key players in the market:

Some of the key players in Biomarker Testing Services Market include: Euro fins Scientific, Abbott Laboratories, Bio Agilytix Labs, Bio-Rad Laboratories, Inc., Charles River Laboratories, Epigenetics AG, F. Hoffmann-La Roche Ltd., ICON Plc, Intertek Group Plc, IQVIA, Johnson & Johnson Services, Inc., Labcorp Drug Development, Qiagen, SGS SA, Siemens Healthineers AG, Syneos Health and Thermo Fisher Scientific, Inc.

Key Developments:

In September 2023, QIAGEN announced the expansion of its clinical decision support software, QIAGEN Clinical Insight Interpret (QCI Interpret), to include artificial intelligence (AI)-enhanced coverage of thousands of rare disease genes, advancing its AI-capabilities that have been established for over two decades. The expansion complements the human-certified content curation of QCI Interpret and enables complete bibliographical coverage of the clinical exome.

In July 2023, Quanterix Corporation, a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced it has launched LucentAD, a test to assist in the evaluation of patients experiencing cognitive symptoms consistent with the early signs of Alzheimer's disease (AD). The LucentAD test, which will be available to healthcare providers as an aid in conjunction with other diagnostic tools, provides clinicians with a simplified process to quickly assess the likelihood of a patient having amyloid pathology consistent with AD. This information will help healthcare providers determine appropriate follow up and treatment planning for a suspected Alzheimer's patient.

In June 2023, JennyCo, Inc., a first-of-its-kind healthcare data exchange powered by Web3, has announced that it has partnered with AYUMETRIX, a leading provider of laboratory testing services.

Testing Types Covered:

  • Biomarker Testing
  • Cell-based Assays
  • Method Development Optimization and Validation
  • Pharmacokinetic Testing
  • Serology Immunogenicity and Neutralizing Antibodies
  • Toxicology Services
  • Virology Testing
  • Other Testing Types

Technologies Covered:

  • Mass Spectrometry
  • Chromatography

Applications Covered:

  • Neurology
  • Cardiology
  • Gastroenterology
  • Hematology
  • Immunology
  • Infectious Diseases
  • Metabolic Disorders
  • Oncology
  • Orthopedics
  • Other Applications

End Users Covered:

  • Biopharmaceutical and Pharmaceutical Companies
  • Contract Development and Manufacturing Organizations
  • Contract Research Organizations
  • Healthcare Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Biomarker Testing Services Market, By Testing Type

  • 5.1 Introduction
  • 5.2 Biomarker Testing
  • 5.3 Cell-based Assays
  • 5.4 Method Development Optimization and Validation
  • 5.5 Pharmacokinetic Testing
  • 5.6 Serology Immunogenicity and Neutralizing Antibodies
  • 5.7 Toxicology Services
  • 5.8 Virology Testing
  • 5.9 Other Testing Types

6 Global Biomarker Testing Services Market, By Technology

  • 6.1 Introduction
  • 6.2 Mass Spectrometry
  • 6.3 Chromatography

7 Global Biomarker Testing Services Market, By Application

  • 7.1 Introduction
  • 7.2 Neurology
  • 7.3 Cardiology
  • 7.4 Gastroenterology
  • 7.5 Hematology
  • 7.6 Immunology
  • 7.7 Infectious Diseases
  • 7.8 Metabolic Disorders
  • 7.9 Oncology
  • 7.10 Orthopedics
  • 7.11 Other Applications

8 Global Biomarker Testing Services Market, By End User

  • 8.1 Introduction
  • 8.2 Biopharmaceutical and Pharmaceutical Companies
  • 8.3 Contract Development and Manufacturing Organizations
  • 8.4 Contract Research Organizations
  • 8.5 Healthcare Institutes
  • 8.6 Other End Users

9 Global Biomarker Testing Services Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Euro fins Scientific
  • 11.2 Abbott Laboratories
  • 11.3 Bio Agilytix Labs
  • 11.4 Bio-Rad Laboratories, Inc.
  • 11.5 Charles River Laboratories
  • 11.6 Epigenetics AG
  • 11.7 F. Hoffmann-La Roche Ltd.
  • 11.8 ICON Plc
  • 11.9 Intertek Group Plc
  • 11.10 IQVIA
  • 11.11 Johnson & Johnson Services, Inc.
  • 11.12 Labcorp Drug Development
  • 11.13 Qiagen
  • 11.14 SGS SA
  • 11.15 Siemens Healthineers AG
  • 11.16 Syneos Health
  • 11.17 Thermo Fisher Scientific, Inc.

List of Tables

  • 1 Global Biomarker Testing Services Market Outlook, By Region (2021-2030) ($MN)
  • 2 Global Biomarker Testing Services Market Outlook, By Testing Type (2021-2030) ($MN)
  • 3 Global Biomarker Testing Services Market Outlook, By Biomarker Testing (2021-2030) ($MN)
  • 4 Global Biomarker Testing Services Market Outlook, By Cell-based Assays (2021-2030) ($MN)
  • 5 Global Biomarker Testing Services Market Outlook, By Method Development Optimization and Validation (2021-2030) ($MN)
  • 6 Global Biomarker Testing Services Market Outlook, By Pharmacokinetic Testing (2021-2030) ($MN)
  • 7 Global Biomarker Testing Services Market Outlook, By Serology Immunogenicity and Neutralizing Antibodies (2021-2030) ($MN)
  • 8 Global Biomarker Testing Services Market Outlook, By Toxicology Services (2021-2030) ($MN)
  • 9 Global Biomarker Testing Services Market Outlook, By Virology Testing (2021-2030) ($MN)
  • 10 Global Biomarker Testing Services Market Outlook, By Other Testing Types (2021-2030) ($MN)
  • 11 Global Biomarker Testing Services Market Outlook, By Technology (2021-2030) ($MN)
  • 12 Global Biomarker Testing Services Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
  • 13 Global Biomarker Testing Services Market Outlook, By Chromatography (2021-2030) ($MN)
  • 14 Global Biomarker Testing Services Market Outlook, By Application (2021-2030) ($MN)
  • 15 Global Biomarker Testing Services Market Outlook, By Neurology (2021-2030) ($MN)
  • 16 Global Biomarker Testing Services Market Outlook, By Cardiology (2021-2030) ($MN)
  • 17 Global Biomarker Testing Services Market Outlook, By Gastroenterology (2021-2030) ($MN)
  • 18 Global Biomarker Testing Services Market Outlook, By Hematology (2021-2030) ($MN)
  • 19 Global Biomarker Testing Services Market Outlook, By Immunology (2021-2030) ($MN)
  • 20 Global Biomarker Testing Services Market Outlook, By Infectious Diseases (2021-2030) ($MN)
  • 21 Global Biomarker Testing Services Market Outlook, By Metabolic Disorders (2021-2030) ($MN)
  • 22 Global Biomarker Testing Services Market Outlook, By Oncology (2021-2030) ($MN)
  • 23 Global Biomarker Testing Services Market Outlook, By Orthopedics (2021-2030) ($MN)
  • 24 Global Biomarker Testing Services Market Outlook, By Other Applications (2021-2030) ($MN)
  • 25 Global Biomarker Testing Services Market Outlook, By End User (2021-2030) ($MN)
  • 26 Global Biomarker Testing Services Market Outlook, By Biopharmaceutical and Pharmaceutical Companies (2021-2030) ($MN)
  • 27 Global Biomarker Testing Services Market Outlook, By Contract Development and Manufacturing Organizations (2021-2030) ($MN)
  • 28 Global Biomarker Testing Services Market Outlook, By Contract Research Organizations (2021-2030) ($MN)
  • 29 Global Biomarker Testing Services Market Outlook, By Healthcare Institutes (2021-2030) ($MN)
  • 30 Global Biomarker Testing Services Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.